Advertisement
Interested parties may access the call by dialing 800-762-8795 from withinthe United States, or 480-629-9031 if calling internationally. The conferenceID is 3924338. It is advisable to dial in approximately 5-10 minutes prior tothe start of the call. A replay will be available through October 13, 2008and can be accessed by dialing 800-406-7325 (U.S.), 303-590-3030 (Int'l),passcode 3924338.
Advertisement
This call is being web cast by ViaVid Broadcasting and can be accessed atViaVid's website at http://viavid.net or at the following link:http://viavid.net/dce.aspx?sid=00005691 . The web cast can be accessed untilOctober 29, 2008. To access the web cast, you will need to have the WindowsMedia Player on your desktop. For the free download of the Media Playerplease visit:http://microsoft.com/windows/windowsmedia/en/download/default.asp .
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 33 modernized TCMs and 4 generic western medicines in the market,22 of which are listed in the highly selective National Medicine Catalog ofthe National Medical Insurance Program. Tianyin owns and operates two GMPmanufacturing facilities and an R&D platform supported by leading Chineseacademic institutions. The Company has a pipeline of 48 pharmaceuticalproducts pending approval. Tianyin has an extensive nationwide distributionnetwork throughout China with a sales force of 720 salespeople. Tianyin isheadquartered in Chengdu, Sichuan Province with two manufacturing facilitiesand a total of 1,384 employees. Tianyin achieved revenue of $20.4 million andnet income of $3.95 million in FY2007 ending June 30, 2007. For moreinformation about Tianyin Pharmaceuticals, please visithttp://tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO China Tel: +86-158-2122-5642 Email: [email protected] Investors: HC International, Inc. Alan Sheinwald US Tel: +1-914-669-0222 Email: [email protected]
SOURCE Tianyin Pharmaceutical, Co., Inc.
